Prognostic Factors Affecting Hearing in Otitis Media With ANCA-Associated Vasculitis Patients: A Systematic Review and Meta-Analysis

• Published in: Ear, nose, & throat journal nose, & throat journal, 2023-10, p.1455613231200488-1455613231200488
• Main Authors: Li, Chen, Xie, Mengyao, Wu, Zhiyuan, Wang, Shu, Han, Zhijin, Tang, Qi, Xue, Ruoyan, Zhang, Yongli, Yang, Hua
• Format: Article
• Language: English
• ISSN: 0145-5613; 1942-7522
• DOI: 10.1177/01455613231200488

To conduct a systematic review and meta-analysis of clinical studies describing the possible prognostic factors affecting hearing outcomes in Otitis media with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (OMAAV) patients. To provide guidance for clinical work, avoiding profound irreversible hearing loss affecting patients' lives. A literature search was performed in PubMed, MEDLINE, EMBASE, Cochrane, Scopus, and Web of Science to identify English articles published before December 1, 2022. After screening the articles, the Newcastle-Ottawa Scale (NOS) was used to assess the risk of bias of the extracted literature, and studies with high quality (score > 6) were included. Four studies were included: 1 was a retrospective cohort study, and 3 were case-control studies. We performed a meta-analysis of 4 factors: facial palsy, hypertrophic pachymeningitis, ANCA-negative status, and the period from onset to diagnosis. The results showed that there was a significant association between facial palsy [odds ratio (OR) 1.51; 95% confidence interval (CI) 1.07-2.15; = 0%; = .02], hypertrophic pachymeningitis (OR 1.73; 95% CI 1.18-2.53; = 24%; = .005), ANCA negativity (OR 1.75; 95% CI 1.11-2.77; = 33; = .02), and poor hearing prognosis in OMAAV patients. However, the period from onset to diagnosis (SEM ± SD 2.54; 95% CI -1.56 to 6.64; = 98%; = .22) of OMAAV was not significantly associated with poor hearing outcomes. We found that OMAAV patients with facial palsy, hypertrophic pachymeningitis, and ANCA negativity have a significant association with poor hearing prognosis, which provides diagnosis and treatment guidance in protecting patients' hearing.